OVX-003

OVX-003 is an investigational sustained-release ophthalmic therapeutic candidate being developed by Ocuvex Therapeutics for the treatment of ocular diseases, specifically ocular inflammation. The asset utilizes Ocuvex's proprietary drug delivery technology, which focuses on bio-erodible sustained-release inserts designed to provide prolonged therapeutic levels of the active pharmaceutical ingredient in the eye. While specific molecular details are often proprietary in early development, OVX-003 is identified in company pipeline documentation as a Phase 2 candidate targeting ophthalmic conditions. It is part of a broader portfolio of sustained-release ocular products that includes treatments for glaucoma and dry eye disease.